Goldman Sachs Group Inc. lessened its holdings in Achieve Life Sciences, Inc. (NASDAQ:ACHV – Free Report) by 27.0% in the first quarter, HoldingsChannel.com reports. Goldman Sachs Group Inc.’s holdings in Achieve Life Sciences were worth $295,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Get Achieve Life Sciences alerts:Achieve Life Sciences Price PerformanceAchieve Life Sciences stock opened at $3.01 on Friday. Check Out Our Latest Stock Analysis on Achieve Life SciencesAchieve Life Sciences Company Profile(Free Report)Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.